Dr. Reddy’s and Nestlé Health Science launch Celevida GLP+ for people undergoing GLP-1/GIP therapy in India.

Collaboration between Dr. Reddy’s Laboratories Ltd and Nestlé India Limited has launched Celevida GLP+, a scientifically designed nutritional product developed to support people undergoing GLP-1/GIP therapy for the management of type 2 diabetes and obesity in India. 

The launch comes at a time when GLP-1/GIP-based therapies are witnessing wider adoption for diabetes and obesity management. While these therapies improve access to advanced treatment options, experts emphasise the need for a more integrated patient-care ecosystem that extends beyond medication. Such an ecosystem should include nutrition support, clinical monitoring, and long-term patient guidance to ensure sustainable and holistic health outcomes. 

According to Towards Healthcare, the therapeutic clinical nutrition market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 66.76 billion in 2026 to approximately USD 132.89 billion by 2035, representing a compound annual growth rate (CAGR) of 7.95% from 2026 to 2035. Growth is driven by the increase in conditions like diabetes, cancer, and gastrointestinal diseases, necessitating specialized nutrition for management and recovery, and the rise of tailored nutrition plans based on genetic and metabolic testing is fueling a market shift toward specialized formulas. 

CEO, Global Generics at Dr. Reddy's Laboratories Ltd. and Director, Dr. Reddy's and Nestlé Health Science Ltd, M.V. Ramana says, "GLP-1 therapies represent a significant advancement in diabetes and obesity management. However, a clear unmet need remains in supporting patients beyond pharmacological treatment, particularly in addressing nutrition gaps and preserving muscle health during therapy. 

Addressing Nutrition Gaps During GLP-1/GIP Therapy 

Highlighting the importance of addressing nutritional deficiencies and muscle health challenges associated with GLP-1/GIP therapies, experts have stated that nearly 25–40% of total weight loss during GLP-1 and dual GLP-1/GIP therapies may result from the loss of lean body mass. 

Senior Indian clinicians further noted that Indians may face a higher risk of muscle loss because they generally have lower baseline skeletal muscle mass and higher body fat percentages. Additionally, chronically low protein intake among Indians is estimated at around 0.6 g/kg/day. As a result, preserving muscle mass has become critical for maintaining long-term metabolic and functional health. 

A recent report by Towards Healthcare highlights that the therapeutic clinical nutrition market is witnessing growth due to the demand for tailored nutritional plans, which are on the rise, offering targeted support based on individual health profiles. The market is shifted toward sustainability with initiatives to improve food availability, minimize waste, and ensure robust, sustainable food systems, which are creating opportunities for nutrient-dense diets and regenerative agriculture.